Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysRichard L. Mackman, Tomáš Cihlář, B. Michael O’Keefe et al.|Journal of Medicinal Chemistry|2023Cited by 63
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infectionMeghan S. Vermillion, Danielle Porter, Eisuke Murakami et al.|Science Translational Medicine|2021Cited by 42
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infectionJared Pitts, John P. Bilello, Darius Babusis et al.|Antiviral Research|2022Cited by 13
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeysJared Pitts, John P. Bilello, J. Lizbeth Reyes Zamora et al.|Nature Communications|2025Cited by 6
539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for ObeldesivirJared Pitts, John P. Bilello, Darius Babusis et al.|Open Forum Infectious Diseases|2023Cited by 3